STOCK TITAN

Schedule 13G: Nantahala, Harkey & Mack Hold 5.29% of TLSI

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G

Rhea-AI Filing Summary

TriSalus Life Sciences received a Schedule 13G reporting that Nantahala Capital Management, LLC and its managing members, Wilmot B. Harkey and Daniel Mack, each may be deemed the beneficial owner of 2,000,000 shares of TriSalus common stock, representing 5.29% of the class as of June 30, 2025. The filing states the shares are held by funds and separately managed accounts under Nantahala's control, and the reported position reflects shared voting and dispositive power only, with no sole voting or sole dispositive authority. The Reporting Persons certify the shares were acquired in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Positive

  • Material disclosure: Reporting of a >5% position (5.29%) increases transparency for investors
  • Passive intent stated: Certification that shares were acquired in the ordinary course and not to influence control

Negative

  • No sole voting or dispositive power: Reporting Persons do not have unilateral control over the shares

Insights

TL;DR: A single adviser and its principals report a >5% stake (5.29%), signalling a material passive stake with shared control only.

The Schedule 13G shows Nantahala and two principals collectively control 2,000,000 shares, meeting the disclosure threshold for a passive investor under Rule 13d-1. The position is reported with shared voting and dispositive power and no sole authority, which suggests coordinated reporting across affiliated accounts rather than concentrated ownership by one individual. The certification that the stake is held in the ordinary course and not to influence control reduces the likelihood of imminent activism, but the >5% ownership is material and may attract market attention depending on trading volume and float.

TL;DR: Ownership crosses the 5% disclosure threshold but shows no sole control, implying limited governance influence at this stage.

The filing attributes shared voting and dispositive powers to Nantahala and its managing members, indicating the stake is held across funds/accounts managed by the adviser. Because there is no sole voting power, the Reporting Persons lack unilateral ability to direct corporate actions. The explicit certification that the holdings are not intended to change control is consistent with a passive investment profile, though ongoing monitoring of future filings would be warranted to detect any shift toward active engagement.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Nantahala Capital Management, LLC
Signature:/s/ Taki Vasilakis
Name/Title:Taki Vasilakis / Chief Compliance Officer
Date:08/14/2025
Wilmot B. Harkey
Signature:/s/ Wilmot B. Harkey
Name/Title:Wilmot B. Harkey
Date:08/14/2025
Daniel Mack
Signature:/s/ Daniel Mack
Name/Title:Daniel Mack
Date:08/14/2025

FAQ

What stake did Nantahala Capital report in TriSalus Life Sciences (TLSI)?

The filing reports Nantahala and its managing members beneficially own 2,000,000 shares, equal to 5.29% of the class as of June 30, 2025.

Do the reporting persons have voting control over the TLSI shares?

No; the Schedule 13G shows 0 sole voting power and 2,000,000 shares of shared voting power, indicating no unilateral voting control.

Was the TLSI stake acquired to influence control of the company?

According to Item 10 certification, the Reporting Persons state the shares were acquired and are held in the ordinary course of business and not to change or influence control of the issuer.

Who filed the Schedule 13G for TLSI and where is the filer located?

The filing was made by Nantahala Capital Management, LLC and individuals Wilmot B. Harkey and Daniel Mack; the business address is 130 Main St. 2nd Floor, New Canaan, Connecticut 06840.

When does the reported ownership snapshot apply?

The ownership percentages and share counts are reported as of June 30, 2025.
TriSalus Life Sciences Inc.

NASDAQ:TLSI

TLSI Rankings

TLSI Latest News

TLSI Latest SEC Filings

TLSI Stock Data

293.29M
28.03M
40.92%
17.25%
0.92%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
WESTMINSTER